ACADIA Pharmaceuticals Inc.
General ticker "ACAD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $3.4B (TTM average)
ACADIA Pharmaceuticals Inc. follows the US Stock Market performance with the rate: 52.0%.
Estimated limits based on current volatility of 1.8%: low 21.32$, high 22.11$
Factors to consider:
- Total employees count: 654 (+9.4%) as of 2024
- Top business risk factors: Commercialization challenges, Leadership changes, Economic downturns and volatility, Supply chain disruptions, Acquisition/divestiture risks
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [22.23$, 36.88$]
- 2026-12-31 to 2027-12-31 estimated range: [24.07$, 39.47$]
Financial Metrics affecting the ACAD estimates:
- Positive: with PPE of 12.8 at the end of fiscal year the price was neutral
- Positive: 7.68 < Operating profit margin, % of 9.78
- Positive: 0.07 < Operating cash flow per share per price, % of 2.38
- Positive: Return on assets ratio (scaled to [-100,100]) of 20 > 6.12
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: Shareholder equity ratio, % of 78.47 > 64.25
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ACAD quotes
Long-term ACAD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $726.44MM | $957.80MM | $1,071.51MM |
| Operating Expenses | $799.82MM | $727.00MM | $966.69MM |
| Operating Income | $-73.38MM | $230.79MM | $104.81MM |
| Non-Operating Income | $22.34MM | $27.28MM | $34.09MM |
| R&D Expense | $351.62MM | $303.25MM | $328.80MM |
| Income(Loss) | $-51.04MM | $258.07MM | $138.90MM |
| Taxes | $10.25MM | $31.62MM | $-252.10MM |
| Profit(Loss)* | $-61.29MM | $226.45MM | $391.00MM |
| Stockholders Equity | $431.75MM | $732.79MM | $1,227.39MM |
| Inventory | $35.82MM | $21.95MM | $34.67MM |
| Assets | $748.96MM | $1,187.76MM | $1,564.19MM |
| Operating Cash Flow | $16.70MM | $157.72MM | $109.84MM |
| Capital expenditure | $40.05MM | $0.52MM | $4.69MM |
| Investing Cash Flow | $32.00MM | $-30.54MM | $-302.56MM |
| Financing Cash Flow | $25.13MM | $6.84MM | $49.88MM |
| Earnings Per Share** | $-0.37 | $1.37 | $2.31 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.